Loading prices…
On Zipp since 2026
Listed on

REGNon is the Ondo Tokenized representation of Regeneron Pharmaceuticals, a biotechnology company listed on U.S. equity markets. The token is designed to give holders economic exposure comparable to holding the underlying REGN stock, including the reinvestment of any dividends distributed by the company. It is issued within the Ondo Finance tokenization framework, which operates across multiple blockchain networks, including Ethereum, BNB Chain, and Solana. The token belongs to the broader category of tokenized real-world assets, specifically tokenized equities, bridging traditional financial instruments with decentralized blockchain infrastructure. It is intended for non-U.S. retail and institutional users who can mint and redeem the tokenized stock around the clock during standard trading days, gaining access to traditional exchange liquidity without requiring direct brokerage access in U.S. markets. Certain jurisdictional and regulatory restrictions apply to participation. Additional information about the product and its terms is available through Ondo Finance's global markets platform.

Regeneron Pharmaceuticals (Ondo Tokenized) (REGNON) yet to make Zipp headlines

When Zipp's editorial pipeline picks up a Regeneron Pharmaceuticals (Ondo Tokenized) story, it lands here first. Until then, here are three useful paths:

Regeneron Pharmaceuticals (Ondo Tokenized) (REGNON) — FAQ

  1. What is Regeneron Pharmaceuticals (Ondo Tokenized)?

    REGNon is the Ondo Tokenized version of Regeneron Pharmaceuticals, giving tokenholders economic exposure similar to holding REGN and reinvesting any dividends.

  2. What kind of project is Regeneron Pharmaceuticals (Ondo Tokenized)?

    Regeneron Pharmaceuticals (Ondo Tokenized) (REGNON) is categorised as: Tokenized Assets, BNB Chain Ecosystem, Solana Ecosystem.

  3. Where is Regeneron Pharmaceuticals (Ondo Tokenized)'s official website?

    The official Regeneron Pharmaceuticals (Ondo Tokenized) site is https://app.ondo.finance/.